IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
- 07 November 2023 - 1 mins read
| Statement of transactions in own shares from October 30 to November 03, 2023 | BNP PARIBAS | ||||||||||
| Aggregated presentation by day and by market | |||||||||||
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 30/10/2023 | FR0010259150 | 22 | 111.80 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 30/10/2023 | FR0010259150 | 240 | 111.70 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 30/10/2023 | FR0010259150 | 41 | 111.90 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 30/10/2023 | FR0010259150 | 1,908 | 111.83 | XPAR | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 31/10/2023 | FR0010259150 | 41 | 112.10 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 31/10/2023 | FR0010259150 | 161 | 112.80 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 31/10/2023 | FR0010259150 | 226 | 112.70 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 31/10/2023 | FR0010259150 | 2,572 | 112.95 | XPAR | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 01/11/2023 | FR0010259150 | 182 | 112.72 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 01/11/2023 | FR0010259150 | 286 | 112.96 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 01/11/2023 | FR0010259150 | 47 | 112.94 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 01/11/2023 | FR0010259150 | 2,485 | 112.84 | XPAR | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 02/11/2023 | FR0010259150 | 289 | 112.09 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 02/11/2023 | FR0010259150 | 165 | 112.57 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 02/11/2023 | FR0010259150 | 92 | 112.05 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 02/11/2023 | FR0010259150 | 2,454 | 112.68 | XPAR | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 03/11/2023 | FR0010259150 | 162 | 110.80 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 03/11/2023 | FR0010259150 | 94 | 110.93 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 03/11/2023 | FR0010259150 | 4 | 110.70 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 03/11/2023 | FR0010259150 | 2,740 | 111.09 | XPAR | |||||
| * Two-digit rounding after the decimal | TOTAL | 14,211 | 112.27 | ||||||||
Attachment
14 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
13 November 2023
11 mins read
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...
03 October 2023
5 mins read
Ipsen updates on QM-1114 regulatory process
26 September 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
04 September 2023
5 mins read
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
21 August 2023
15 mins read
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
18 July 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023
26 May 2023
7 mins read
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
09 June 2022
6 mins read
Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or...
27 October 2021
3 mins read